The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period
- PMID: 29961742
- PMCID: PMC6058582
- DOI: 10.5535/arm.2018.42.3.441
The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period
Abstract
Objective: To investigate appropriate treatment time and useful bone turnover markers (BTMs) for monitoring bone turnover during the postmenopausal period, we analyzed changes of two bone resorption markers; serum carboxyterminal telopeptide of collagen I (s-CTX), urine deoxypyridinoline (u-DPD), one bone formation marker; serum osteocalcin (s-OC), and bone mineral density (BMD) in Korean postmenopausal women.
Methods: Seventy-eight menopausal women were divided into three groups according to postmenopausal period: group I (0-5 years), group II (6-10 years), group III (≥10 years). All groups were subdivided into an osteoporosis group (T-score≤-2.5) and a non-osteoporosis group (T-score>-2.5). BTMs such as s-CTX, u-DPD, s-OC, and BMD (g/cm2) were measured by dual-energy X-ray absorptiometry (DXA) in all patients. Analysis of variables among groups based on the postmenopausal period was performed using ANOVA.
Results: There was significant negative correlation between BMD and postmenopausal period. The levels of all BTMs including s-CTX, u-DPD, and s-OC were highest in group II and the increased levels of all BTMs subsequently declined in group III. The levels of BTMs were higher in the osteoporosis groups than in the non-osteoporosis groups in all subjects. It was statistically significant that the level of s-CTX in group I was higher in the osteoporosis group than in the non-osteoporosis group.
Conclusion: This study showed that bone resorption and bone formation were the highest 5-10 years after menopause, and s-CTX is more useful than u-DPD among the bone resorption markers. It's important to measure serially both BMD and BTM within 10 years after menopause for accurate diagnosis and management for postmenopausal osteoporosis.
Keywords: Biomarker; Bone density; Osteoporosis; Postmenopause.
Figures
Similar articles
-
Osteoporosis Markers.2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32644732 Free Books & Documents.
-
Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.J Obstet Gynaecol Res. 2009 Feb;35(1):152-9. doi: 10.1111/j.1447-0756.2008.00868.x. J Obstet Gynaecol Res. 2009. PMID: 19215563
-
Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.Bone. 2010 Oct;47(4):804-14. doi: 10.1016/j.bone.2010.07.017. Epub 2010 Jul 23. Bone. 2010. PMID: 20659600
-
Bisphosphonates for prevention of postmenopausal osteoporosis.Dan Med Bull. 2002 Feb;49(1):1-18. Dan Med Bull. 2002. PMID: 11894721 Review.
-
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment.J Bone Metab. 2019 Nov;26(4):213-224. doi: 10.11005/jbm.2019.26.4.213. Epub 2019 Nov 30. J Bone Metab. 2019. PMID: 31832387 Free PMC article. Review.
Cited by
-
Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.J Mol Med (Berl). 2024 Feb 16. doi: 10.1007/s00109-024-02418-8. Online ahead of print. J Mol Med (Berl). 2024. PMID: 38363329 Review.
-
Changes in bone mineral density and clinical parameters after stroke in elderly patients with osteopenia.Medicine (Baltimore). 2024 Jan 26;103(4):e37028. doi: 10.1097/MD.0000000000037028. Medicine (Baltimore). 2024. PMID: 38277561 Free PMC article.
-
Polydatin administration attenuates the severe sublesional bone loss in mice with chronic spinal cord injury.Aging (Albany NY). 2022 Nov 15;14(21):8856-8875. doi: 10.18632/aging.204382. Epub 2022 Nov 15. Aging (Albany NY). 2022. PMID: 36378815 Free PMC article.
-
Association of bone-related biomarkers with femoral neck bone strength.BMC Musculoskelet Disord. 2022 May 21;23(1):482. doi: 10.1186/s12891-022-05427-1. BMC Musculoskelet Disord. 2022. PMID: 35597928 Free PMC article.
-
A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.Front Med (Lausanne). 2021 Sep 8;8:717168. doi: 10.3389/fmed.2021.717168. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34568375 Free PMC article.
References
-
- Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646–50. - PubMed
-
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95. - PubMed
-
- Kim G. Immobilization osteoporosis. Osteoporosis. 2011;9:1–17.
-
- Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med. 1986;314:1676–86. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
